Review
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 7, 2016; 22(1): 361-368
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.361
Gut microbiota in autism and mood disorders
Francesca Mangiola, Gianluca Ianiro, Francesco Franceschi, Stefano Fagiuoli, Giovanni Gasbarrini, Antonio Gasbarrini
Francesca Mangiola, Gianluca Ianiro, Francesco Franceschi, Antonio Gasbarrini, Catholic University, School of Medicine, 00168 Rome, Italy
Francesca Mangiola, Gianluca Ianiro, Francesco Franceschi, Antonio Gasbarrini, Department of Internal Medicine, Division of Internal Medicine, Gastroenterology and Liver Disease; “A. Gemelli” University Hospital, 00168 Rome, Italy
Stefano Fagiuoli, Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy
Giovanni Gasbarrini, “Ricerca in Medicina” ONLUS Foundation, 40121 Bologna, Italy
Author contributions: All authors contributed to the manuscript.
Conflict-of-interest statement: No conflict-of-interest declared.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Antonio Gasbarrini, MD, Professor, Catholic University, School of Medicine, Largo F. Vito 1, 00168 Rome, Italy. agasbarrini@rm.unicatt.it
Telephone: +39-63-156018 Fax: +39-63-157249
Received: June 9, 2015
Peer-review started: June 11, 2015
First decision: September 11, 2015
Revised: October 9, 2015
Accepted: November 11, 2015
Article in press: November 11, 2015
Published online: January 7, 2016

Abstract

The hypothesis of an important role of gut microbiota in the maintenance of physiological state into the gastrointestinal (GI) system is supported by several studies that have shown a qualitative and quantitative alteration of the intestinal flora in a number of gastrointestinal and extra-gastrointestinal diseases. In the last few years, the importance of gut microbiota impairment in the etiopathogenesis of pathology such as autism, dementia and mood disorder, has been raised. The evidence of the inflammatory state alteration, highlighted in disorders such as schizophrenia, major depressive disorder and bipolar disorder, strongly recalls the microbiota alteration, highly suggesting an important role of the alteration of GI system also in neuropsychiatric disorders. Up to now, available evidences display that the impairment of gut microbiota plays a key role in the development of autism and mood disorders. The application of therapeutic modulators of gut microbiota to autism and mood disorders has been experienced only in experimental settings to date, with few but promising results. A deeper assessment of the role of gut microbiota in the development of autism spectrum disorder (ASD), as well as the advancement of the therapeutic armamentarium for the modulation of gut microbiota is warranted for a better management of ASD and mood disorders.

Key Words: Gut microbiota, Mood disorders, Autism, Depression, Gut microbiota modulation, Fecal microbiota transplantation

Core tip: Up to now, available evidences display that the impairment of gut microbiota plays a key role in the development of autism and mood disorders. The application of therapeutic modulators of gut microbiota to autism and mood disorders has been experienced only in experimental settings to date, with few but promising results, that suggest the microbiota modulation as a therapeutic approach for autism and mood disorders.


Citation: Mangiola F, Ianiro G, Franceschi F, Fagiuoli S, Gasbarrini G, Gasbarrini A. Gut microbiota in autism and mood disorders. World J Gastroenterol 2016; 22(1): 361-368
INTRODUCTION

The gut microbiota, composed of thousands of different microbial species and more than 15000 kinds of bacteria for a weight equal to 1 kg, represents the first protection system of the gastrointestinal (GI) apparatus. The presence of the microbiota varies within the gastrointestinal tract, from few micro-organisms in the stomach and small intestine, up to a concentration of approximately 1.012 bacteria in the colon, mostly represented by the Firmicutes and Bacteriodetes phyla[1,2]. Within the species that compose the microbiota, it’s also possible to recognize the kingdom of Archaea and eukaryotes, and many viruses and bacteriophages[3,4]. Finally, there were several families of fungi, whose physiological role in the gastrointestinal system is still unclear.

The functions performed by the flora are manifold; in addition to the contribution to the establishment of the intestinal barrier, it promotes its maintenance, stimulating epithelial regeneration through the production of short chain fatty acids (SCFAs), leading to mucus production and exerting a trophic action on the mucous membrane[5].

The gut microbiota is involved in the maturation of the immune system: it stimulates innate immunity in the early years of life, leading to the maturation of the GALT, and acquired immunity, through stimulation of local and systemic immune responses[6]. Known, finally, is the role in the synthesis and metabolism of certain nutrients, hormones and vitamins, and clearance of drugs and toxic.

The human body, completely sterile at birth, is immediately in contact with a large amount of microbial communities, including the fecal, vaginal and skin microbiota of the mother. Subsequently, the composition of the flora undergoes changes, influenced by age, sex, state of immune maturation and by environmental factors.

The flora acquires its stability between 6 and 36 mo of life; in that period it’s already possible to distinguish between a constant endogenous flora (core microbiota) and a still provisional one, highly sensitive to external stimuli[7,8].

In physiological conditions, the continuous stimulation of the immune system by the gut microbiota leads to a state of “low-grade physiological inflammation”, which is a rapid and effective mechanism of defence against pathogens[9]. In addition, the flora exerts its protective role competitively, metabolizing those nutrients needed for pathogens survival, and producing molecules that inhibit the growth of such microbes[10].

Sonnenburg et al[11] has shown that the introduction of a compound of Bacteroides thetaiotamicron and Eubacterium rectale is able to induce the production of particular mucosal glycans, which may be metabolized exclusively by these bacterial species and not by pathogens, thus preventing their proliferation.

The hypothesis of an important role of gut microbiota in the maintenance of physiological state into the GI system is supported by several studies that have shown a qualitative and quantitative alteration of the intestinal flora in a number of gastrointestinal and extra-gastrointestinal diseases.

GUT MICROBIOTA AND PSYCHIATRIC DISORDERS: A FOCUS ON AUTISM SPECTRUM DISORDER AND MOOD DISORDERS

Recent data show the strong correlation between dysbiosis and conditions such as obesity, allergies, autoimmune disorders, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and psychiatric disorders[12-16].

Due to these new evidences about the fundamental role of gut microbiota in the alteration of immune, neural, and endocrine pathways, the so-called “gut-brain axis” is acquiring new significance, even if the communication routes are not still defined[16-18].

At the beginning of the past century, first hypotheses aroused about the correlation between these two systems; probably the most practice evidence can be found in a work of an army surgeon, who noted the correlation between a patient’s gut function and his mood, monitoring gastric secretions through a fistula in his stomach[13].

In the last few years, much research has been done in this direction, underlying the importance of dysbiosis in the etiopathogenesis of pathology such as autism, dementia and mood disorder. The evidence of the inflammatory state alteration, highlighted in disorders such as schizophrenia, major depressive disorder and bipolar disorder[19-23], strongly recalls the microbiota alteration and highly suggests an important role of the alteration of GI system also in neuropsychiatric disorders.

In particular, the dysbiosis and the consequent alteration of intestinal permeability lead respectively to the production and spread into the bloodstream of a potent pro-inflammatory endotoxine, namely lipopolysaccharide (LPS). This small molecule has an important influence in the modulation of the central nervous system (CNS), increasing the activity of areas deputed to the emotionalism control such as amygdala[24]. It also lead to production of inflammatory cytokines that alter the physiological brain activity, modulating the neuropeptides synthesis[25].

Rhee et al[26] highlighted the importance of bidirectional connections between gut and brain that occurs in both healthy and diseased states focusing attention on enterochromaffin cells. The signals generated by the stimulation of these pathways due to intraluminal gut stimuli, running on nervous system, strongly modulate the brain activity, including pain perception, immune-response modulation, emotional control and many other homeostatic functions.

However, this influence is not unidirectional, but is a continuous communication: the CNS is able to change the composition of microbiota and to alter the equilibrium in the gut permeability, modulating motility and secretion through the activation of the hypothalamus pituitary-adrenal (HPA) axis, autonomic and neuroendocrine system with an immediate impact on gut microbiota[26,27]. In this regard O’Mahony et al[28], showed that early maternal separation in rats increased corticosterone systemic level, resulting in the alteration of immune response and fecal microbiota. Among several actors of this axis, important molecules have been studied such as vasoactive intestinal peptide (VIP) serotonin, melatonin, gamma-aminobu- tyric acid (GABA), catecholamines, histamine and acetylcholine[29-32], even if interaction way and acting routes of these molecules is not fully established.

Autism spectrum disorder (ASD) is a range of developmental neuro-behavioral disorders characterized by restricted and repetitive behaviour, impaired social interaction and communication; among these, autism represents the primary type of ASD[12,16].

The possible role of gut microorganism in the pathogenesis of such disorders has been widely deepened by several studies in animal models using different approaches: comparison of gut microbiota composition between affected samples an controls; observation of behaviour changes after administration of gut microbiota modulators in affected subjects rather than virulence factors in controls.

It has been demonstrated that a large amount of species under the Clostridium genus (10 times more) characterised the qualitative composition of fecal samples of autistic children[33-35]. Then, the composition of microbiota has been characterized, showing an imbalance of Bacteroidetes and Firmicutes phyla, with an increased presence of Bacteroidetes and other gut commensal such as Bifidobacterium, Lactobacillus, Sutterella, Prevotella, Ruminococcus genera and Alcaligenaceae family[36-40].

In the 1998, Bolte[41] observed that a significant percentage of individuals with autism had a history of extensive antibiotic use that significantly disrupt protective intestinal microbiota. On this basis, he outlined the possibility of a subacute, chronic tetanus infection of the intestinal tract that underlies the pathogenesis of symptoms in autism observed in some individuals.

Sandler et al[42] speculated that the alteration of autochthonous gut flora microbiota leads to the colonization by bacteria able to produce neurotoxins, contributing, at least in part, to their autistic symptomatology. On this basis, they treated a small group of children affected by regressive-onset autism with poor oral absorption-antibiotic. At the end of treatment, short-term improvement was noted using multiple pre- and post-therapy evaluations.

It has been also studied the consequences of gut barrier alteration contribute to ASD. A study carried on by Emanuele et al[43] showed that LPS serum levels were significantly higher in autistic patients compared to heath individuals and correlated with socialization scores in an inverse and independent manner. These evidences support a role of microbiota and, generally, of an alteration of the gut barrier in its integrity, in the genesis of ASD.

Nevertheless, the existence of a gastrointestinal dysbiosis as an actor in the ASD etiopathogenesis remains a controversial topic. In this regard, the study carried on by Gondalia et al[44] didn’t showed clinically meaningful differences in the gut microbiota characterization between children affected by autism and their neurotypical siblings.

Depression is a major form of mood disorder characterized by depressed mood and/or recurrent thoughts of death and/or loss of interest or pleasure in life activities present over a period of at least 2 wk, accompanied by at least five additional symptoms that cause clinically significant impairment in social, work, or other important areas of functioning[13]. It results from neuro-psychiatric disturbance, immunological deregulation, genetic factors and environmental influences; nevertheless, a correlation with gut microbiota is emerging[45-47]; Through humoral route, microbiota can also influence CNS neurotransmission: it has been demonstrated that in GF mice anxiety-like behavior is reduced and modulated after restoration of the intestinal microbiota[48-50]. In particular, administration of Lactobacillus sp, Bifidobacteria sp, L. helvetucys, B. longum, L. rhamnosus and Lactobacillus farciminis in murine sample lay to an improvement of depression and anxiety symptoms[51].

In particular, an alteration of intestinal permeability, causing high level of LPS into the bloodstream, lead to the activation of inflammatory and immune response; these processes have been hypothesized as causative factors in psychiatric disorders such as depression[52,53]. Moreover, as support to this hypothesis, it has been demonstrated that the administration of LPS in healthy subject is associated to increase of pro-inflammatory cytokines and plasma norepinephrine, whit higher depression rates[54].

Among clinical studies conducted, gut microbiota has been characterized, showing an overexpression of Alistipes in patients affected by depression disorder[47]. The overexpression of this bacterium, a genus in the phylum of Bacteroidetes, has been demonstrated in other disorders, such as chronic fatigue syndrome and in IBS[55,56]. This evidence lead to speculate about a gut microbiota alteration as common mechanism of action in the genesis of these disorders. Moreover, Alistipes has been linked to depression mood by generation of inflammatory molecules able to spread into the bloodstream in condition of altered intestinal permeability[47,51,57]. Another study, carried on by Jiang et al[58], confirmed the overexpression of Alistipes in psychiatric disorder and observed a negative correlation between expression of Faecalibacterium and the severity of depressive manifestations. An overview of main alterations of gut microbiota in autism and depression is available in Table 1.

Table 1 Alterations of gut microbiota found in autism and mood disorders.
DiseaseMicrobiota alterations
AutismImbalance of Bacteroidetes/Firmicutes ratio
Increase of Bacteroidetes phylum, Bifidobacterium, Lactobacillus, Sutterella, Prevotella, Ruminococcus genera, Alcaligenaceae family
DepressionIncrease of Alistipes
Negative correlation between Faecalibacterium abundance and severity of disease
POTENTIAL FOR THERAPEUTICS
Antibiotics

Antibiotics are the oldest drugs used in the management of diseases of the gastrointestinal tract. Their use, especially for infectious diseases, can achieve an alteration of the composition of the gut microbiota that can lead to significant side effects, not the least of antibiotic-associated diarrhoea due to Clostridium difficile[59]. Despite this, the antibiotic therapy is currently encouraged in the management of disorders such as IBS, IBD and SIBO in which the modulation of the intestinal flora leading to a net clinical improvement.

Currently, researches are being made in order to clarify the modulation of gut microbiota in the management of psychiatric disorder. It has been demonstrated that reduction of luminal LPS concentration due to antibiotic therapy lead to attenuation of HPA axis stress response and to increase of hypothalamic pro-inflammatory cytokines expression[60].

Desbonnet et al[61] have reproduced the effect of microbiota depletion on murine specimens: they administered them a combination of antibiotics and then assessed the effects from weaning onwards on adult cognitive, social and emotional behaviours and markers of gut-brain axis dysfunction in mice. They demonstrated that the reduction and diversity of the gut microbiota influences adult behaviours and key neuromodulators of the gut-brain axis: it reduced anxiety, induced cognitive deficits, altered the brain hormone expression and altered dynamics of the tryptophan metabolic pathway.

In support of these findings, some studies have successfully tested minocycline, second-generation tetracycline, as a treatment for depression, on the basis of its neuroprotective activities and regulation of pro-inflammatory agents[62,63].

In an other study, 11 children affected by ASD have been treated with vancomycin: after the planned 8 wk of treatment, communication and behaviour tests improvement has been observed[42].

Thus, it’s possible to speculate that antibiotic treatment, through modulation of gut micriobiota, should be able to influences symptoms and expression of psychiatric disorders.

Probiotics

Probiotics are defined as live micro- organisms, preferentially of human origin, that upon ingestion in specific and sufficient numbers confer non-specific health benefits to the host[64].

Currently widely used in gastrointestinal system disorders, they exert their therapeutic effect by interacting on various levels in the reconstitution of the gastrointestinal barrier. In addition to a direct effect in the composition of Gut Microbiota, they are able to modulate the GI barrier through the increase of mucin production by globet cells, strengthening the tight junctions and thus the apical intercellular adhesion[65-68].

Probiotics are also involved in the modulation of the immune and inflammatory response by promoting the production of regulatory T cells. They may also regulate the Th1 response, by inhibition the production by the dendritic cells of pro-inflammatory cytokines such as IL-12, TNF-α and INF-α, or increase the expression of anti-inflammatory mediators such as IL-10 and β-TFGF[67].

Some studies tested probiotics as symptoms’ modulator in disorders such as anxiety and depression. For example, Bravo et al[69] demonstrated that chronic administration of L. rhamnosus modulates GABA expression in CNS in rat, leading to a reduction in the hippocampus, amygdala, and locus coeruleus and to an increase in cortical regions. Furthermore, it reduces levels of corticosterone induced by stress and depression- and anxiety-related symptoms. In particular, these events didn’t appear in vagotomised mice, indicating a fundamental role of vagal sings, and generally of neuronal transmission, in the gut-brain axis.

Similarly, combination of L. helveticus and B. longum appears to have an anxiolytic-like activity in rats and, in addition to a diet formulation containing high levels of polyunsaturated fatty acids (PUFAs) n-3, to reduce post-MI depression[70,71].

Despite these impressive results, few clinical trials have been conducted with poor results. A double-blind, randomized clinical trial demonstrated that the daily administration of mixture of probiotics containing L. helveticus and B. longum for a month reduce psychological distress in healthy controls[70].

Rao et al[72] showed that the daily administration of Lactobacillus casei for two months improves anxiety related symptoms in subject affected by chronic fatigue syndrome[58].

However, the daily assumption of L. casei enriched milk didn’t show significant effects in term of mood in healthy individuals while seemed to have potentially negative effects on recall memory[73].

Finally, Hsiao et al[74] showed that the oral administration of Bacteroides fragilis, improved some mood symptoms- such as anxiety, stereotypical behaviour and sensorimotor gating-in a maternal immune activation (MIA) animal model that is known to display features of ASD.

Fecal microbiota transplantation

Fecal microbiota transplantation (FMT) represents the injection of filtrate stools from a healthy donor to a patient for the healing of a specific disease. Despite it had been sporadically used in ancient times, its first application in contemporary medicine in English literature, dates back 1958, when Ben Eiseman infused fecal material in four patients with pseudomembranous colitis[75]. After this pioneering experience, several attempts were reported over time for the treatment of C. difficile infection. To date, several systematic reviews and meta-analyses[76-78], as well as three randomized controlled trials[79-81], outlined the undoubted efficacy of FMT for the treatment of recurrent C. difficile infection. Some proof-of-concept randomized controlled trials investigated the efficacy of FMT in metabolic syndrome[82] and IBD, respectively[83,84]. In particular, it has been reported that FMT improved sexual function in patients with Crohn’s diseases: this finding might get stronger the connection between of gut microbiota and depression/mood[85]. At present, despite the theoretical background for the application of FMT to autism is sound, to date it was experienced only in two autistic children, in whom it showed an amelioration of specific symptoms[86].

CONCLUSION

In the last few years, the importance of gut microbiota in the maintenance of physiological state into the GI system is supported by several studies that have shown a qualitative and quantitative alteration of the intestinal flora in a number of gastrointestinal and extra-gastrointestinal diseases. The application of gut microbiota modulators, such as probiotics, antibiotics, up to FMT, has been widely experimented as therapeutic instrument for GI diseases with exciting results.

Up to now, available evidences display that the impairment of gut microbiota plays a key role also in the development of autism and mood disorders, but the mechanism through which it does is not fully clear. The application of therapeutic modulators of gut microbiota to autism and mood disorders has been experienced only in experimental settings to date, with few but promising results.

A deeper assessment of the role of intestinal flora in the genesis and development of mood disorders and ASD is currently required; the knowledge advancement of the modulation of the intestinal flora not only about possible modalities but also about the timing in which this should be done, would lead to a new and safe therapeutic weapon in the management of ASD and mood disorders.

Footnotes

P- Reviewer: Nakamura S, Zhang FM S- Editor: Qi Y L- Editor: A E- Editor: Wang CH

References
1.  Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.  [PubMed]  [DOI]
2.  Schmidt C, Stallmach A. Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol. 2005;51:127-145.  [PubMed]  [DOI]
3.  Eckburg PB, Lepp PW, Relman DA. Archaea and their potential role in human disease. Infect Immun. 2003;71:591-596.  [PubMed]  [DOI]
4.  Breitbart M, Hewson I, Felts B, Mahaffy JM, Nulton J, Salamon P, Rohwer F. Metagenomic analyses of an uncultured viral community from human feces. J Bacteriol. 2003;185:6220-6223.  [PubMed]  [DOI]
5.  Burger-van Paassen N, Vincent A, Puiman PJ, van der Sluis M, Bouma J, Boehm G, van Goudoever JB, van Seuningen I, Renes IB. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J. 2009;420:211-219.  [PubMed]  [DOI]
6.  Nell S, Suerbaum S, Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol. 2010;8:564-577.  [PubMed]  [DOI]
7.  Scaldaferri F, Pizzoferrato M, Gerardi V, Lopetuso L, Gasbarrini A. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol. 2012;46 Suppl:S12-S17.  [PubMed]  [DOI]
8.  Round JL, O’Connell RM, Mazmanian SK. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun. 2010;34:J220-J225.  [PubMed]  [DOI]
9.  Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229-241.  [PubMed]  [DOI]
10.  Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859-904.  [PubMed]  [DOI]
11.  Sonnenburg ED, Zheng H, Joglekar P, Higginbottom SK, Firbank SJ, Bolam DN, Sonnenburg JL. Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota alterations. Cell. 2010;141:1241-1252.  [PubMed]  [DOI]
12.  Fond G, Boukouaci W, Chevalier G, Regnault A, Eberl G, Hamdani N, Dickerson F, Macgregor A, Boyer L, Dargel A. The “psychomicrobiotic”: Targeting microbiota in major psychiatric disorders: A systematic review. Pathol Biol (Paris). 2015;63:35-42.  [PubMed]  [DOI]
13.  Zhou L, Foster JA. Psychobiotics and the gut-brain axis: in the pursuit of happiness. Neuropsychiatr Dis Treat. 2015;11:715-723.  [PubMed]  [DOI]
14.  Natividad JM, Verdu EF. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharmacol Res. 2013;69:42-51.  [PubMed]  [DOI]
15.  de Silva HJ, Millard PR, Soper N, Kettlewell M, Mortensen N, Jewell DP. Effects of the faecal stream and stasis on the ileal pouch mucosa. Gut. 1991;32:1166-1169.  [PubMed]  [DOI]
16.  Wang Y, Kasper LH. The role of microbiome in central nervous system disorders. Brain Behav Immun. 2014;38:1-12.  [PubMed]  [DOI]
17.  Dinan TG, Cryan JF. The impact of gut microbiota on brain and behaviour: implications for psychiatry. Curr Opin Clin Nutr Metab Care. 2015;18:552-558.  [PubMed]  [DOI]
18.  Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10:735-742.  [PubMed]  [DOI]
19.  Müller N, Myint AM, Schwarz MJ. Inflammation in schizophrenia. Adv Protein Chem Struct Biol. 2012;88:49-68.  [PubMed]  [DOI]
20.  Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-741.  [PubMed]  [DOI]
21.  Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35:804-817.  [PubMed]  [DOI]
22.  O’Malley D, Quigley EM, Dinan TG, Cryan JF. Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome? Brain Behav Immun. 2011;25:1333-1341.  [PubMed]  [DOI]
23.  Castro-Nallar E, Bendall ML, Pérez-Losada M, Sabuncyan S, Severance EG, Dickerson FB, Schroeder JR, Yolken RH, Crandall KA. Composition, taxonomy and functional diversity of the oropharynx microbiome in individuals with schizophrenia and controls. PeerJ. 2015;3:e1140.  [PubMed]  [DOI]
24.  Haba R, Shintani N, Onaka Y, Wang H, Takenaga R, Hayata A, Baba A, Hashimoto H. Lipopolysaccharide affects exploratory behaviors toward novel objects by impairing cognition and/or motivation in mice: Possible role of activation of the central amygdala. Behav Brain Res. 2012;228:423-431.  [PubMed]  [DOI]
25.  Kastin AJ, Pan W. Concepts for biologically active peptides. Curr Pharm Des. 2010;16:3390-3400.  [PubMed]  [DOI]
26.  Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009;6:306-314.  [PubMed]  [DOI]
27.  Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13:701-712.  [PubMed]  [DOI]
28.  O’Mahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM, Cryan JF, Dinan TG. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry. 2009;65:263-267.  [PubMed]  [DOI]
29.  Barrett E, Ross RP, O’Toole PW, Fitzgerald GF, Stanton C. γ-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol. 2012;113:411-417.  [PubMed]  [DOI]
30.  Forsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J. Mood and gut feelings. Brain Behav Immun. 2010;24:9-16.  [PubMed]  [DOI]
31.  Lyte M. Probiotics function mechanistically as delivery vehicles for neuroactive compounds: Microbial endocrinology in the design and use of probiotics. Bioessays. 2011;33:574-581.  [PubMed]  [DOI]
32.  Velickovic K, Markelic M, Golic I, Otasevic V, Stancic A, Jankovic A, Vucetic M, Buzadzic B, Korac B, Korac A. Long-term dietary L-arginine supplementation increases endothelial nitric oxide synthase and vasoactive intestinal peptide immunoexpression in rat small intestine. Eur J Nutr. 2014;53:813-821.  [PubMed]  [DOI]
33.  Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, McTeague M, Sandler R, Wexler H, Marlowe EM. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis. 2002;35:S6-S16.  [PubMed]  [DOI]
34.  Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol. 2004;70:6459-6465.  [PubMed]  [DOI]
35.  Parracho HM, Bingham MO, Gibson GR, McCartney AL. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol. 2005;54:987-991.  [PubMed]  [DOI]
36.  Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, Youn E, Summanen PH, Granpeesheh D, Dixon D. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe. 2010;16:444-453.  [PubMed]  [DOI]
37.  Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with autism--comparisons to typical children and correlation with autism severity. BMC Gastroenterol. 2011;11:22.  [PubMed]  [DOI]
38.  Kang DW, Park JG, Ilhan ZE, Wallstrom G, Labaer J, Adams JB, Krajmalnik-Brown R. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS One. 2013;8:e68322.  [PubMed]  [DOI]
39.  Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Increased abundance of Sutterella spp. and Ruminococcus torques in feces of children with autism spectrum disorder. Mol Autism. 2013;4:42.  [PubMed]  [DOI]
40.  Williams BL, Hornig M, Parekh T, Lipkin WI. Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. MBio. 2012;3:pii: e00261-11.  [PubMed]  [DOI]
41.  Bolte ER. Autism and Clostridium tetani. Med Hypotheses. 1998;51:133-144.  [PubMed]  [DOI]
42.  Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Väisänen ML, Nelson MN, Wexler HM. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol. 2000;15:429-435.  [PubMed]  [DOI]
43.  Emanuele E, Orsi P, Boso M, Broglia D, Brondino N, Barale F, di Nemi SU, Politi P. Low-grade endotoxemia in patients with severe autism. Neurosci Lett. 2010;471:162-165.  [PubMed]  [DOI]
44.  Gondalia SV, Palombo EA, Knowles SR, Cox SB, Meyer D, Austin DW. Molecular characterisation of gastrointestinal microbiota of children with autism (with and without gastrointestinal dysfunction) and their neurotypical siblings. Autism Res. 2012;5:419-427.  [PubMed]  [DOI]
45.  Dash S, Clarke G, Berk M, Jacka FN. The gut microbiome and diet in psychiatry: focus on depression. Curr Opin Psychiatry. 2015;28:1-6.  [PubMed]  [DOI]
46.  Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46-56.  [PubMed]  [DOI]
47.  Naseribafrouei A, Hestad K, Avershina E, Sekelja M, Linløkken A, Wilson R, Rudi K. Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil. 2014;26:1155-1162.  [PubMed]  [DOI]
48.  Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil. 2011;23:255-264, e119.  [PubMed]  [DOI]
49.  Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, Dinan TG, Cryan JF. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013;18:666-673.  [PubMed]  [DOI]
50.  Logan AC, Katzman M. Major depressive disorder: probiotics may be an adjuvant therapy. Med Hypotheses. 2005;64:533-538.  [PubMed]  [DOI]
51.  Luna RA, Foster JA. Gut brain axis: diet microbiota interactions and implications for modulation of anxiety and depression. Curr Opin Biotechnol. 2015;32:35-41.  [PubMed]  [DOI]
52.  Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55:453-462.  [PubMed]  [DOI]
53.  Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, Allen NB, Stuart AL, Hayley AC, Byrne ML. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200.  [PubMed]  [DOI]
54.  Grigoleit JS, Kullmann JS, Wolf OT, Hammes F, Wegner A, Jablonowski S, Engler H, Gizewski E, Oberbeck R, Schedlowski M. Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PLoS One. 2011;6:e28330.  [PubMed]  [DOI]
55.  Frémont M, Coomans D, Massart S, De Meirleir K. High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients. Anaerobe. 2013;22:50-56.  [PubMed]  [DOI]
56.  Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology. 2011;141:1782-1791.  [PubMed]  [DOI]
57.  Bangsgaard Bendtsen KM, Krych L, Sørensen DB, Pang W, Nielsen DS, Josefsen K, Hansen LH, Sørensen SJ, Hansen AK. Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse. PLoS One. 2012;7:e46231.  [PubMed]  [DOI]
58.  Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015;48:186-194.  [PubMed]  [DOI]
59.  Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol. 2010;4:409-416.  [PubMed]  [DOI]
60.  Ait-Belgnaoui A, Durand H, Cartier C, Chaumaz G, Eutamene H, Ferrier L, Houdeau E, Fioramonti J, Bueno L, Theodorou V. Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats. Psychoneuroendocrinology. 2012;37:1885-1895.  [PubMed]  [DOI]
61.  Desbonnet L, Clarke G, Traplin A, O’Sullivan O, Crispie F, Moloney RD, Cotter PD, Dinan TG, Cryan JF. Gut microbiota depletion from early adolescence in mice: Implications for brain and behaviour. Brain Behav Immun. 2015;48:165-173.  [PubMed]  [DOI]
62.  Soczynska JK, Mansur RB, Brietzke E, Swardfager W, Kennedy SH, Woldeyohannes HO, Powell AM, Manierka MS, McIntyre RS. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res. 2012;235:302-317.  [PubMed]  [DOI]
63.  Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, Tsuchie K, Taki M, Ishihara K, Araki T. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:222-226.  [PubMed]  [DOI]
64.  Caselli M, Cassol F, Calò G, Holton J, Zuliani G, Gasbarrini A. Actual concept of “probiotics”: is it more functional to science or business? World J Gastroenterol. 2013;19:1527-1540.  [PubMed]  [DOI]
65.  Scaldaferri F, Pizzoferrato M, Pecere S, Forte F, Gasbarrini A. Bacterial flora as a cause or treatment of chronic diarrhea. Gastroenterol Clin North Am. 2012;41:581-602.  [PubMed]  [DOI]
66.  Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010;7:503-514.  [PubMed]  [DOI]
67.  Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis. 2009;15:300-310.  [PubMed]  [DOI]
68.  Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol. 2004;286:G613-G626.  [PubMed]  [DOI]
69.  Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA. 2011;108:16050-16055.  [PubMed]  [DOI]
70.  Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, Bisson JF, Rougeot C, Pichelin M, Cazaubiel M. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011;105:755-764.  [PubMed]  [DOI]
71.  Gilbert K, Arseneault-Bréard J, Flores Monaco F, Beaudoin A, Bah TM, Tompkins TA, Godbout R, Rousseau G. Attenuation of post-myocardial infarction depression in rats by n-3 fatty acids or probiotics starting after the onset of reperfusion. Br J Nutr. 2013;109:50-56.  [PubMed]  [DOI]
72.  Rao AV, Bested AC, Beaulne TM, Katzman MA, Iorio C, Berardi JM, Logan AC. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009;1:6.  [PubMed]  [DOI]
73.  Benton D, Williams C, Brown A. Impact of consuming a milk drink containing a probiotic on mood and cognition. Eur J Clin Nutr. 2007;61:355-361.  [PubMed]  [DOI]
74.  Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, Codelli JA, Chow J, Reisman SE, Petrosino JF. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155:1451-1463.  [PubMed]  [DOI]
75.  Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854-859.  [PubMed]  [DOI]
76.  Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48:693-702.  [PubMed]  [DOI]
77.  Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500-508.  [PubMed]  [DOI]
78.  Drekonja D, Reich J, Gezahegn S, Greer N, Shaukat A, MacDonald R, Rutks I, Wilt TJ. Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review. Ann Intern Med. 2015;162:630-638.  [PubMed]  [DOI]
79.  van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-415.  [PubMed]  [DOI]
80.  Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, Sanguinetti M, Gasbarrini A. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835-843.  [PubMed]  [DOI]
81.  Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, Alm EJ, Gevers D, Russell GH, Hohmann EL. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58:1515-1522.  [PubMed]  [DOI]
82.  Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913-916.e7.  [PubMed]  [DOI]
83.  Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015;149:102-109.e6.  [PubMed]  [DOI]
84.  Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, Löwenberg M, van den Brink GR, Mathus-Vliegen EM, de Vos WM. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015;149:110-118.e4.  [PubMed]  [DOI]
85.  Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, Huang G, Liu Z, Wu P, Fan Z. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30:51-58.  [PubMed]  [DOI]
86.  Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013;29:79-84.  [PubMed]  [DOI]